SRGA.Q'un PS Oranı emsallerine kıyasla nasıldır?

SRGA.Q, Price-To-Sales değerine göre iyi bir değerdir. Eş ortalamaya (0x) kıyasla oran (3.8x).

SRGA.Q'nin PS Oranı, US Medical Equipment Sektöründeki diğer şirketlerle karşılaştırıldığında nasıldır?

SRGA.Q Price-To-Sales Oranı ( 0 x) baz alındığında, US Medical Equipment sektör ortalamasına ( 3.2 x) kıyasla iyi bir değerdir.

SRGA.Q'nin PS Oranı, Adil PS Oranına kıyasla nedir? Bu, şirketin tahmini kazanç büyümesini, kar marjlarını ve diğer risk faktörlerini dikkate alan beklenen PS Oranıdır.

Değerleme analizi için SRGA.Q 'in Price-To-Sales Adil Oranını hesaplamak için yeterli veri yok.

Gelecekteki nakit akışlarına bakıldığında SRGA.Q 'un Adil Fiyatı nedir? Bu tahmin için İndirgenmiş Nakit Akışı modelini kullanıyoruz.

SRGA.Q 'un değerleme analizi için adil değerinin hesaplanmasında yeterli veri bulunmamaktadır.

Analistin 12 aylık tahmini nedir ve konsensüs fiyat hedefine istatistiksel olarak güveniyor muyuz?

Fiyat tahminini göstermek için yeterli veri yok.

Surgalign Holdings (OTCPK:SRGA.Q) - Hisse Senedi Fiyatı, Haberler ve Analizler

SRGA.Q Stoklara Genel Bakış

Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spinal hardware implants and biomaterial products worldwide.

Şirket hakkında

SRGA.Q temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Ödüller

Risk Analizi

Kazançlar son 5 yılda yılda 9.6% oranında azaldı

Anlamlı bir piyasa değeri yok ( $165K )

Negatif hissedar öz sermayesi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

+ 2 daha fazla risk

Surgalign Holdings, Inc. Rakipler

Procyon

OTCPK:PCYN

US$1.5m

InVitro International

OTCPK:IVRO

US$2.0m

Vycor Medical

OTCPK:VYCO

US$2.6m

Arch Therapeutics

OTCPK:ARTH

US$1.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Surgalign Holdings
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.018
52 Haftanın En Yüksek Seviyesi	US$4.00
52 Haftanın En Düşük Seviyesi	US$0.005
Beta	1.49
11 Aylık Değişim	63.64%
3 Aylık Değişim	-80.00%
1 Yıllık Değişim	-99.50%
33 Yıllık Değişim	-99.97%
5 Yıllık Değişim	-99.99%
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

Recent updates

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Aug 24

Hissedar Getirileri

	SRGA.Q	US Medical Equipment	US Pazar
7D	16.1%	1.6%	5.0%
1Y	-99.5%	31.5%	36.1%

Getiri vs. Endüstri: SRGA.Q geçen yıl % 31.5 oranında getiri sağlayan US Medical Equipment sektörünün gerisinde kaldı.

Getiri vs Piyasa: SRGA.Q geçen yıl % 36.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is SRGA.Q's price volatile compared to industry and market?
SRGA.Q volatility
SRGA.Q Average Weekly Movement	40.5%
Medical Equipment Industry Average Movement	7.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.2%
10% least volatile stocks in US Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: SRGA.Q hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: SRGA.Q 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 28% dan 40% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1997	240	Terry Rich	www.surgalign.com

Surgalign Holdings, Inc. Temel Bilgiler Özeti

Surgalign Holdings'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
SRGA.Q temel i̇stati̇sti̇kler
Piyasa değeri	US$165.30k
Kazançlar(TTM)	-US$50.49m
Gelir(TTM)	US$78.12m

0.0x

P/S Oranı

0.0x

F/K Oranı

SRGA.Q aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
SRGA.Q gelir tablosu (TTM)
Gelir	US$78.12m
Gelir Maliyeti	US$26.03m
Brüt Kâr	US$52.09m
Diğer Giderler	US$102.58m
Kazançlar	-US$50.49m

Son Raporlanan Kazançlar

Mar 31, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-5.50
Brüt Marj	66.68%
Net Kâr Marjı	-64.63%
Borç/Özkaynak Oranı	-54.1%

SRGA.Q uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

SRGA.Q Stoklara Genel Bakış

Ödüller

Risk Analizi

Surgalign Holdings, Inc. Rakipler

OTCPK:PCYN

US$1.5m

OTCPK:IVRO

US$2.0m

OTCPK:VYCO

US$2.6m

OTCPK:ARTH

US$1.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Recent updates

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Surgalign Holdings Receives Deficiency Letter from the Nasdaq Stock Market LLC Due to Non-Compliance with Minimum Market Value of Publicly Held Shares

Price target decreased by 19% to US$2.22

Consensus estimates of losses per share improve by 87%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Announces Release of HOLO AI Insights for Neurovascular Research

Surgalign Holdings, Inc. to Report Q1, 2023 Results on May 11, 2023

Consensus revenue estimates fall by 38%

Full year 2022 earnings: EPS misses analyst expectations

Surgalign Holdings, Inc. Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation System

Surgalign Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $11.99474 million.

Price target decreased to US$5.00

Consensus EPS estimates fall by 14%

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Surgalign Holdings, Inc. Lowers Revenue Guidance for 2022

Surgalign Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Surgalign Holdings, Inc Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures

Surgalign Holdings, Inc. Announces Third Clinical Site in the Commercialization of Its Holo Portal™ Surgical Guidance System

Surgalign Announces FDA 510(K) Clearance of the Cortera Spinal Fixation System – the Company’s New Flagship Posterior Fixation Platform

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Surgalign Holdings Announces Asset Impairment for the Second Quarter Ended June 30, 2022

Surgalign revenue of $20.62M misses by $0.51M, reconfirms full-year revenue

Surgalign Holdings, Inc. Appoints Paolo Amoruso as New General Counsel and Corporate Secretary

Surgalign Holdings, Inc. Reaches Settlement with the Securities and Exchange Commission

Surgalign Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Surgalign Holdings, Inc. Announces Clinical Site Expansion in the Commercialization of Its HOLO Portal Surgical Guidance System in Ohio

Chief Financial Officer recently bought US$100k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Surgalign™ Announces the First Successful Surgical Procedure Utilizing Its HOLO Portal™ Surgical Guidance System

Price target decreased to US$1.00

Surgalign Holdings, Inc., Annual General Meeting, May 10, 2022

Joshua H. Derienzis Notifies Surgalign Holdings, Inc. of His Decision to Resign from His Position as Chief Legal Officer and Corporate Secretary, Effective May 10, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Appoints David Lyle as Chief Financial Officer

Surgalign Holdings, Inc. Receives FDA Clearance for HOLO Portal™ System

Surgalign Holdings - A Future Of Digital Surgery

Price target decreased to US$2.85

Third quarter 2021 earnings released: US$0.06 loss per share (vs US$0.36 loss in 3Q 2020)

Sizing Up Surgalign

Independent Director Jeffrey Lightcap has left the company

Chairman Stuart Simpson has left the company

Surgalign Holdings: Insiders Are Buying

Surgalign Holdings, Inc. Announces Issuance of U.S. Patent Covering the Use of Artificial Intelligence in Medical Image Segmentation

President recently bought US$1.0m worth of stock

Surgalign Holdings: Pinocchio Has A Happy Ending

Second quarter 2021 earnings released: US$0.086 loss per share (vs US$0.30 loss in 2Q 2020)

Price target decreased to US$4.21

Surgalign Holdings: A Marketing Ploy

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from Russell 3000E Value Index

Surgalign reports inducement grants under Nasdaq listing rule

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.24 loss in 1Q 2020)